Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody T-cell Enhancer, in Patients With PSMA+ Advanced and/or Metastatic Solid Tumours

Next Previous
Trial Profile

A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody T-cell Enhancer, in Patients With PSMA+ Advanced and/or Metastatic Solid Tumours

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CB 307 (Primary) ; Pembrolizumab (Primary)
  • Indications Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms POTENTIA
  • Sponsors Crescendo Biologics

Most Recent Events

  • 06 Dec 2023 According to a Crescendo Biologics media release, US part of the trial has seen patients successfully dosed in both the monotherapy and combination cohorts at the Fred Hutchinson Cancer Centre. Patients continue to be recruited across European trial sites in the UK, Spain and Netherlands.
  • 06 Dec 2023 According to a Crescendo Biologics media release, the company expands trial beyond Europe with first US trial site, the Fred Hutchinson Cancer Centre, at the University of Washington.
  • 06 Dec 2023 According to a Crescendo Biologics media release, first patient has been dosed in U.S. in the expanded phase 1b trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top